Maravai LifeSciences Expands Its Intellectual Property Portfolio
February 10 2021 - 7:05AM
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, announced today that the United States Patent and
Trademark Office has issued a new patent, United States Patent No.
10,913,768, to the company’s TriLink Biotechnologies subsidiary.
The patent covers advancements in TriLink’s CleanCap® technology
for the co-transcriptional capping of messenger RNAs (mRNAs). This
patent is the third U.S. patent that has issued to the company
related to the CleanCap technology. Capping is an important step in
the production of synthetic mRNA, which is used to develop nucleic
acid vaccines and therapeutics that deliver instructions to human
cells to produce proteins that may prevent or correct disease.
The technology described by United States Patent No. 10,913,768
facilitates the production of mRNAs and provides a significant
improvement over legacy co-transcriptional capping methods.
“Capping is a critical process in creating viable mRNA
constructs that remain biologically active without eliciting immune
responses,” explains Mike Houston, Ph.D., Chief Scientific Officer
of Maravai. “By changing the capping approach and streamlining the
manufacturing workflow, we deliver a novel solution, whether
customers purchase CleanCap in bulk for their own mRNA development
programs or utilize mRNA synthesized by TriLink BioTechnologies
that already incorporates this novel capping technology.”
CleanCap overcomes many drawbacks of existing approaches,
enabling highly-efficient, reproducible production of capped mRNA.
CleanCap technology allows capping to occur in a single reaction,
streamlining the manufacturing of mRNA at large scales. Reduced
manufacturing time is critical for a number of emerging
applications, such as the development of personalized cancer
therapeutics and during rapid vaccine responses to pandemics.
CleanCap also reduces the cost of mRNA manufacturing, further
accelerating the adoption of new mRNA therapeutics.
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, novel vaccines and to
support research on human diseases. Maravai’s companies are leaders
in providing products and services in the fields of nucleic acid
synthesis, bioprocess impurity detection and analysis, and protein
labeling and detection to many of the world's leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.
About TriLink BioTechnologiesTriLink
BioTechnologies, part of Maravai LifeSciences, is a CDMO helping
life science leaders and innovators overcome challenges in the
synthesis and scale-up of nucleic acids, NTPs and mRNA capping
analogs with scale-up expertise and unique mRNA production
capabilities, including its proprietary CleanCap mRNA capping
technology. TriLink continues to expand its cGMP and general
manufacturing capacity at its new global headquarters to support
mRNA, oligonucleotide & DNA plasmid therapeutic, vaccine and
diagnostic customers. www.trilinkbiotech.com
Forward-looking StatementsThis press release
may contain "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release which are not strictly historical statements
constitute forward-looking statements, including, without
limitation, statements related to the advantages of CleanCap
technology, the cost of mRNA manufacturing, and acceleration of new
mRNA vaccines and therapeutics, constitute forward-looking
statements identified by words like “expect,” “may,” “anticipate,”
or “could” and similar expressions. Such forward-looking statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including, without limitation and uncertainties related to
continued validation of the safety and effectiveness of our
technology, new scientific developments and competition from other
products. These and other risks and uncertainties are described in
greater detail in the section entitled “Risk Factors” in Maravai’s
Form S-1 Prospectus on file with the U.S. Securities and Exchange
Commission. Actual results may differ materially from those
contemplated by these forward-looking statements, and therefore you
should not rely upon them. These forward-looking statements reflect
our current views and we do not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.
Contact Information:
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024